Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Donna Stock-Novack"'
Autor:
Christopher J. Jolles, David S. Alberts, B A Dava Garcia, Robert O'toole, Edward V. Hannigan, Vinay K. Malviya, Donna Stock-Novack, Steve Dahlberg, Earl A. Surwit, Stephanie Green
Publikováno v:
Cancer. 71:618-627
The purpose of this study was to evaluate the effect of age (i.e., less than 65 years or 65 years of age and older) on survival in a recently completed phase III Southwest Oncology Group study in ovarian cancer patients.Multivariate and univariate re
Autor:
Gerald Lorch, D.Dennis Hansen, Joel Scherer, Jenny S. Martin, Bradley G. Titus, Donna Stock-Novack, Alfred P. Hallstrom, W. Douglas Weaver, Nathan R. Every, Patrick A. Cambier, Anthony Fung, Jennifer J. Lee
Publikováno v:
American Heart Journal. 138:696-704
Background Previous clinical studies have shown that direct antithrombins can accelerate clot lysis after treatment with streptokinase in acute myocardial infarction (MI). Efegatran is a new direct antithrombin, which in experimental animals has been
Autor:
Vinay K. Malvlya, Edward V. Hannigan, Robert V. O'Toole, David S. Alberts, Patricia F. Anderson, Earl A. Surwit, William A. Nahhas, Stephanie J. Green, Christopher J. Jolles, Donna Stock-Novack
Publikováno v:
Journal of Clinical Oncology. 10:706-717
PURPOSE To compare cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide as primary chemotherapy for stage III (suboptimal) and stage IV ovarian cancer. PATIENTS AND METHODS Three hundred forty-two patients were randomly assigned to treatmen
Publikováno v:
Blood. 78:3281-3287
In 1982 a randomized trial of either alternating or syncopated VMCP/VBAP regimens for the treatment of active multiple myeloma was begun (Southwest Oncology Group Study 8229/30). A concurrent investigation was undertaken to evaluate the clinical impo
Autor:
Paul R. Finley, John Crowley, Jean Beckord, Brian G.M. Durie, Sydney E. Salmon, Charles A. Coltman, Donna Stock-Novack
Publikováno v:
Blood. 75:823-830
Six hundred twelve eligible, previously untreated patients with active multiple myeloma and at least some data available for analysis were entered into a randomized trial (Southwest Oncology Group [SWOG] Phase III myeloma study 8229/30), in which the
Autor:
Edward V. Hannigan, Donna Stock-Novack, Laurence H. Baker, David S. Alberts, Richard Kronmal, Earl A. Surwit, John G. Boutselis
Publikováno v:
Journal of Clinical Oncology. 5:1791-1795
Cisplatin has proven to be the most active single agent in the treatment of metastatic and recurrent squamous cell cancer of the cervix. In a previous southwest Oncology Group (SWOG) pilot study, the addition of cisplatin to a mitomycin-C, vincristin